# A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

> **NCT02034097** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Foretinib
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02034097
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2014-04
- **Final completion:** 2016-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** GSK has decided to terminate the Product Development of foretinib and conclude our Development Agreement with Exelixis
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034097, "A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02034097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*